Page last updated: 2024-11-13

cudraflavanone a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cudraflavanone A: antineoplastic from Cudrania tricuspidata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21721847
CHEMBL ID220746
MeSH IDM0515940

Synonyms (6)

Synonym
cudraflavanone a
bdbm50193719
(s)-5,7,7''-trihydroxy-2'',2''-dimethyl-6-(3-methylbut-2-enyl)-2,6''-bichroman-4-one
(s)-5,7-dihydroxy-2-(7-hydroxy-2,2-dimethyl-2h-chromen-6-yl)-6-(3-methylbut-2-enyl)chroman-4-one
CHEMBL220746 ,
(2s)-5,7-dihydroxy-2-(7-hydroxy-2,2-dimethylchromen-6-yl)-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one

Research Excerpts

Actions

ExcerptReferenceRelevance
"Cudraflavanone A was shown to inhibit the activity of topoisomerase I with approximately 0.4 mmol/l 50% inhibitory concentration."( Cudraflavanone A purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells, at least in part, through the inhibition of DNA topoisomerase I and protein kinase C activity.
Bae, YS; Lee, BW; Park, KH; Rho, YH, 2007
)
2.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phosphotyrosine protein phosphatase Mycobacterium tuberculosisIC50 (µMol)5.09931.20005.04898.5114AID1402907
Sterol O-acyltransferase 2Homo sapiens (human)IC50 (µMol)24.80000.11003.20369.2000AID276035
Pancreatic triacylglycerol lipaseSus scrofa (pig)IC50 (µMol)6.50000.00401.10246.5000AID1242901
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)4.31000.00053.49849.7600AID1402909
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)82.40000.02501.79758.0000AID276034
Low molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37RvIC50 (µMol)2.74002.74005.39678.8000AID1402908
Tyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)IC50 (µMol)9.54001.10004.69009.5400AID1402911
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
cholesterol metabolic processSterol O-acyltransferase 2Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 2Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 2Homo sapiens (human)
intestinal cholesterol absorptionSterol O-acyltransferase 2Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 2Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 2Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 2Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
symbiont-mediated suppression of host apoptosisLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
tissue regenerationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipid metabolic processTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-8 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of natural killer cell proliferationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphoanandamide dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of innate immune responseTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cellular response to muramyl dipeptideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of p38MAPK cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
fatty-acyl-CoA bindingSterol O-acyltransferase 2Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
protein bindingSterol O-acyltransferase 2Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 2Homo sapiens (human)
acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
kinase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
brush borderSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
cytosolLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
podosomeTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
focal adhesionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cell projectionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1402909Inhibition of human PTP1B using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID448783Noncompetitive inhibition of Clostridium welchii neuraminidase by Dixon plot2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural characteristics of flavanones and flavones from Cudrania tricuspidata for neuraminidase inhibition.
AID1402910Selectivity index, ratio of IC50 for human PTP1B to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1402906Selectivity index, ratio of IC50 for Mycobacterium tuberculosis PtpA to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID448782Inhibition of Clostridium welchii neuraminidase2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Structural characteristics of flavanones and flavones from Cudrania tricuspidata for neuraminidase inhibition.
AID276034Inhibition of human ACAT1 expressed in Hi5 cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID292582Inhibition at monoamine oxidase in mouse brain2007Journal of natural products, Jul, Volume: 70, Issue:7
Prenylated xanthones from the root bark of Cudrania tricuspidata.
AID276033Antioxidant activity against human plasma LDL oxidation by TBARS assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID1402913Inhibition of PTP-PEST (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1242902Inhibition of porcine pancreatic lipase at 100 ug/ml pre-incubated for 15 mins before p-nitrophenylbutyrate substrate addition by microplate reader based method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Benzylated and prenylated flavonoids from the root barks of Cudrania tricuspidata with pancreatic lipase inhibitory activity.
AID1402908Inhibition of Mycobacterium tuberculosis PtpA using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1402912Selectivity index, ratio of IC50 for LYP (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1402907Inhibition of Mycobacterium tuberculosis PtpB using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1242903Mixed type inhibition of porcine pancreatic lipase pre-incubated for 15 mins before p-nitrophenylbutyrate substrate addition by Lineweaver-Burk plot method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Benzylated and prenylated flavonoids from the root barks of Cudrania tricuspidata with pancreatic lipase inhibitory activity.
AID1402911Inhibition of LYP (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID276035Inhibition of human ACAT2 expressed in Hi5 cells2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
AID1242901Inhibition of porcine pancreatic lipase pre-incubated for 15 mins before p-nitrophenylbutyrate substrate addition by microplate reader based method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Benzylated and prenylated flavonoids from the root barks of Cudrania tricuspidata with pancreatic lipase inhibitory activity.
AID1402914Selectivity index, ratio of IC50 for PTP-PEST (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]